Last reviewed · How we verify
Nucleos(t)tide analogues
Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase enzymes, preventing viral nucleic acid synthesis and replication.
Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase enzymes, preventing viral DNA synthesis and replication. Used for Chronic hepatitis B, HIV infection, Chronic hepatitis C (in combination regimens).
At a glance
| Generic name | Nucleos(t)tide analogues |
|---|---|
| Also known as | Nucleoside/nucleotide analogues |
| Sponsor | King Abdullah International Medical Research Center |
| Drug class | Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor |
| Target | Viral reverse transcriptase; viral polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These drugs are nucleoside or nucleotide derivatives that are incorporated into viral DNA or RNA during replication, causing chain termination and blocking further viral genome synthesis. They are commonly used to treat infections caused by retroviruses (HIV) and hepatitis viruses (HBV, HCV) by reducing viral load and slowing disease progression.
Approved indications
- Chronic hepatitis B infection
- HIV infection
- Chronic hepatitis C infection (select agents)
Common side effects
- Lactic acidosis
- Hepatotoxicity
- Nausea
- Headache
- Fatigue
- Mitochondrial toxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: